BMJ 2002;325:619 ( 21 September )

Papers

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

Editorial by Jones
See also p 624

Jonathan J Deeks, senior medical statistician, ^a Lesley A Smith, research fellow, ^a Matthew D Bradley, associate director. ^b

^a Centre for Statistics in Medicine, Institute of Health Sciences, Headington, Oxford OX3 7LF, ^b Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ

Correspondence to: J J Deeks
jon.deeks{at}cancer.org.uk

Objective: To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis.
Design: Systematic review of randomised trials that compared at least 12 weeks' celecoxib treatment with another non-steroidal anti-inflammatory drug (NSAID) or placebo and reported efficacy, tolerability, or safety. Trials identified from manufacturer and by searching electronic databases and evaluated according to predefined inclusion and quality criteria. Data combined through meta-analysis.
Participants: 15 187 patients with osteoarthritis or rheumatoid arthritis.
Main outcome measures: Efficacy: Western Ontario and McMaster universities osteoarthritis index; American College of Rheumatology responder index and joint scores for rheumatoid arthritis. Tolerability: withdrawal rates for adverse effects. Gastrointestinal safety: incidence of ulcers, bleeds, perforations, and obstructions.
Results: Nine randomised controlled trials were included. Celecoxib and NSAIDS were equally effective for all efficacy outcomes. Compared with those taking other NSAIDs, in patients taking celecoxib the rate of withdrawals due to adverse gastrointestinal events was 46% lower (95% confidence interval 29% to 58%; NNT 35 at three months), the incidence of ulcers detectable by endoscopy was 71% lower (59% to 79%; NNT 6 at three months), and the incidence of symptoms of ulcers, perforations, bleeds, and obstructions was 39% lower (4% to 61%; NNT 208 at six months). Subgroup analysis of patients taking aspirin showed that the incidence of ulcers detected by endoscopy was reduced by 51% (14% to 72%) in those given celecoxib compared with other NSAIDs. The reduction was greater (73%, 52% to 84%) in those not taking aspirin.
Conclusion: Celecoxib is as effective as other NSAIDs for relief of symptoms of osteoarthritis and rheumatoid arthritis and has significantly improved gastrointestinal safety and tolerability.

What is already known on this topic Long term NSAID use is associated with the development of peptic and duodenal ulcers COX 2 specific inhibitors are claimed to cause fewer gastrointestinal complications The National Institute for Clinical Excellence has recently recommended that COX 2 specific inhibitors are used in patients with arthritis who are at risk of gastrointestinal complications but not in those taking prophylactic aspirin What this study adds Systematic review of randomised trials shows that celecoxib is as effective as other NSAIDs for osteoarthritis and rheumatoid arthritis Celecoxib has significantly improved gastrointestinal safety and tolerability compared with standard NSAIDs An improvement in gastrointestinal safety was still evident in patients who were also taking aspirin

---

© BMJ 2002
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Authors' reply on Cochrane reviews v industry supported meta-analyses

Anders W Jørgensen, Peter C Gøtzsche, and Jørgen Hilden
BMJ 2006 333: 1072-1073. [Extract] [Full Text] [PDF]

Word limits best explain failings of industry supported meta-analyses

Jonathan J Deeks
BMJ 2006 333: 1021. [Extract] [Full Text] [PDF]

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option

Michael R Lewis and Diana Kay
BMJ 2005 331: 1474. [Extract] [Full Text]

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis

Peter Jüni, Rebekka Sterchi, Paul Dieppe, Scott Metcalfe, Sean Dougherty, Wayne McNee, Jonathan J Deeks, Lesley A Smith, and Matthew D Bradley
BMJ 2003 326: 334. [Extract] [Full Text] [PDF]

Celecoxib is as effective as other NSAIDs
BMJ 2002 325: 0. [Full Text] [PDF]

Efficacy and safety of COX 2 inhibitors

Roger Jones
BMJ 2002 325: 607-608. [Extract] [Full Text] [PDF]

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

Muhammad Mamdani, Paula A Rochon, David N Juurlink, Alex Kopp, Geoffrey M Anderson, Gary Naglie, Peter C Austin, and Andreas Laupacis
BMJ 2002 325: 624. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Hoes, J N, Jacobs, J W G, Boers, M, Boumpas, D, Buttgereit, F, Caeyers, N, Choy, E H, Cutolo, M, Da Silva, J A P, Esselens, G, Guillevin, L, Hafstrom, I, Kirwan, J R, Rovensky, J, Russell, A, Saag, K G, Svensson, B, Westhovens, R, Zeidler, H, Bijlsma, J W J (2007). EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66: 1560-1567 [Abstract] [Full text]  
• Lane, N. E. (2007). Osteoarthritis of the Hip. NEJM 357: 1413-1421 [Full text]  
• Scott, P A, Kingsley, G H, Smith, C M, Choy, E H, Scott, D L (2007). Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66: 1296-1304 [Abstract] [Full text]  
• Hunt, R. H., Choquette, D., Craig, B. N., De Angelis, C., Habal, F., Fulthorpe, G., Stewart, J. I., Turpie, A. G.G., Davis, P. (2007). Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. cfp 53: 1177-1184 [Abstract] [Full text]  
• Porcheret, M., Jordan, K., Croft, P., in collaboration with the Primary Care Rheumatolog, (2007). Treatment of knee pain in older adults in primary care: development of an evidence-based model of care. Rheumatology (Oxford) 46: 638-648 [Abstract] [Full text]  
• Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., Moher, D. (2007). Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. ANN INTERN MED 146: 376-389 [Abstract] [Full text]  
• Rahme, E., Bardou, M., Dasgupta, K., Toubouti, Y., Ghosn, J., Barkun, A. N. (2007). Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 46: 265-272 [Abstract] [Full text]  
• Jorgensen, A. W, Gotzsche, P. C, Hilden, J. (2006). Authors' reply on Cochrane reviews v industry supported meta-analyses. BMJ 333: 1072-1073 [Full text]  
• Deeks, J. J (2006). Word limits best explain failings of industry supported meta-analyses. BMJ 333: 1021-1021 [Full text]  
• Chaiamnuay, S., Allison, J. J., Curtis, J. R. (2006). Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.. Am J Health Syst Pharm 63: 1837-1851 [Abstract] [Full text]  
• Rahme, E., Toubouti, Y., Hunsche, E. (2006). Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheumatology (Oxford) 45: 903-910 [Abstract] [Full text]  
• Sooriakumaran, P (2006). COX-2 inhibitors and the heart: are all coxibs the same?. Postgrad. Med. J. 82: 242-245 [Abstract] [Full text]  
• Zochling, J, van der Heijde, D, Dougados, M, Braun, J (2006). Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65: 423-432 [Abstract] [Full text]  
• Zochling, J, van der Heijde, D, Burgos-Vargas, R, Collantes, E, Davis, J C Jr, Dijkmans, B, Dougados, M, Geher, P, Inman, R D, Khan, M A, Kvien, T K, Leirisalo-Repo, M, Olivieri, I, Pavelka, K, Sieper, J, Stucki, G, Sturrock, R D, van der Linden, S, Wendling, D, Bohm, H, van Royen, B J, Braun, J (2006). ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65: 442-452 [Abstract] [Full text]  
• Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., Bradley, J. D., Bingham, C. O. III, Weisman, M. H., Jackson, C. G., Lane, N. E., Cush, J. J., Moreland, L. W., Schumacher, H. R. Jr., Oddis, C. V., Wolfe, F., Molitor, J. A., Yocum, D. E., Schnitzer, T. J., Furst, D. E., Sawitzke, A. D., Shi, H., Brandt, K. D., Moskowitz, R. W., Williams, H. J. (2006). Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.. NEJM 354: 795-808 [Abstract] [Full text]  
• Bjordal, J M, Lopes-Martins, R A B, Iversen, V V, Chow, R (2006). A randomised, placebo controlled trial of low level laser therapy for activated Achilles tendinitis with microdialysis measurement of peritendinous prostaglandin E2 concentrations * Commentary. Br. J. Sports. Med. 40: 76-80 [Abstract] [Full text]  
• Lewis, M. R, Kay, D. (2005). Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option. BMJ 331: 1474-1474 [Full text]  
• Koleva, D., Krulichova, I., Bertolini, G., Caimi, V., Garattini, L. (2005). Pain in primary care: an Italian survey. Eur J Public Health 15: 475-479 [Abstract] [Full text]  
• Cao, Y., Shi, Y., Zheng, Y., Shi, M., Lo, S. K. (2005). Blood-nourishing and Hard-softening Capsule Costs Less in the Management of Osteoarthritic Knee Pain: A Randomized Controlled Trial. Evid Based Complement Alternat Med 2: 363-368 [Abstract] [Full text]  
• Zhang, W, Doherty, M, Arden, N, Bannwarth, B, Bijlsma, J, Gunther, K-P, Hauselmann, H J, Herrero-Beaumont, G, Jordan, K, Kaklamanis, P, Leeb, B, Lequesne, M, Lohmander, S, Mazieres, B, Martin-Mola, E, Pavelka, K, Pendleton, A, Punzi, L, Swoboda, B, Varatojo, R, Verbruggen, G, Zimmermann-Gorska, I, Dougados, M (2005). EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64: 669-681 [Abstract] [Full text]  
• Hull, M.L., Prentice, A., Wang, D.Y., Butt, R.P., Phillips, S.C., Smith, S.K., Charnock-Jones, D.S. (2005). Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod 20: 350-358 [Abstract] [Full text]  
• (2005). Taking stock of coxibs. DTB 43: 1-6 [Abstract] [Full text]  
• Bjordal, J. M., Ljunggren, A. E., Klovning, A., Slordal, L. (2004). Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329: 1317- [Abstract] [Full text]  
• Tannenbaum, H, Berenbaum, F, Reginster, J-Y, Zacher, J, Robinson, J, Poor, G, Bliddal, H, Uebelhart, D, Adami, S, Navarro, F, Lee, A, Moore, A, Gimona, A (2004). Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 63: 1419-1426 [Abstract] [Full text]  
• Hooper, L., Brown, T. J, Elliott, R., Payne, K., Roberts, C., Symmons, D. (2004). The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329: 948- [Abstract] [Full text]  
• Roth, S. H., Shainhouse, J. Z. (2004). Efficacy and Safety of a Topical Diclofenac Solution (Pennsaid) in the Treatment of Primary Osteoarthritis of the Knee: A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial. Arch Intern Med 164: 2017-2023 [Abstract] [Full text]  
• Kranke, P., Morin, A. M., Roewer, N., Eberhart, L. H. (2004). Patients' Global Evaluation of Analgesia and Safety of Injected Parecoxib for Postoperative Pain: A Quantitative Systematic Review. Anesth. Analg. 99: 797-806 [Abstract] [Full text]  
• Briesacher, B., Kamal-Bahl, S., Hochberg, M., Orwig, D., Kahler, K. H. (2004). Three-Tiered-Copayment Drug Coverage and Use of Nonsteroidal Anti-inflammatory Drugs. Arch Intern Med 164: 1679-1684 [Abstract] [Full text]  
• Burgos-Vargas, R., Foeldvari, I., Thon, A., Linke, R., Tuerck, D. (2004). Pharmacokinetics of Meloxicam in Patients With Juvenile Rheumatoid Arthritis. J Clin Pharmacol 44: 866-872 [Abstract] [Full text]  
• Loke, Y. K. (2004). Assessing the benefit-harm balance at the bedside. BMJ 329: 7-8 [Full text]  
• (2004). Beyond the evidence. Arch. Dis. Child. 89: 286-286 [Full text]  
• Layton, D., Hughes, K., Harris, S., Shakir, S. A. W. (2003). Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 42: 1332-1341 [Abstract] [Full text]  
• Pipitone, N., Kingsley, G. H., Manzo, A., Scott, D. L., Pitzalis, C. (2003). Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford) 42: 1138-1148 [Abstract] [Full text]  
• MacDonald, T M, Morant, S V, Goldstein, J L, Burke, T A, Pettitt, D (2003). Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52: 1265-1270 [Abstract] [Full text]  
• Whittle, B J R (2003). New dogmas or old?. Gut 52: 1379-1381 [Abstract] [Full text]  
• Verrico, M. M, Weber, R. J, McKaveney, T. P, Ansani, N. T, Towers, A. L (2003). Adverse Drug Events Involving COX-2 Inhibitors. The Annals of Pharmacotherapy 37: 1203-1213 [Abstract] [Full text]  
• Cuervo, L. G., Clarke, M. (2003). Balancing benefits and harms in health care. BMJ 327: 65-66 [Full text]  
• Haq, I, Murphy, E, Dacre, J (2003). Osteoarthritis. Postgrad. Med. J. 79: 377-383 [Abstract] [Full text]  
• Ng, A., Smith, G., Davidson, A. C. (2003). Analgesic effects of parecoxib following total abdominal hysterectomy{dagger}{ddagger}. Br J Anaesth 90: 746-749 [Abstract] [Full text]  
• Gajraj, N. M. (2003). Cyclooxygenase-2 Inhibitors. Anesth. Analg. 96: 1720-1738 [Full text]  
• Spiegel, B. M.R., Targownik, L., Dulai, G. S., Gralnek, I. M. (2003). The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis. ANN INTERN MED 138: 795-806 [Abstract] [Full text]  
• Symmons, D. (2003). Review: celecoxib is as effective as other NSAIDs and leads to fewer gastrointestinal adverse effects. Evid. Based Med. 8: 51-51 [Full text]  
• Juni, P., Sterchi, R., Dieppe, P., Metcalfe, S., Dougherty, S., McNee, W., Deeks, J. J, Smith, L. A, Bradley, M. D (2003). Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. BMJ 326: 334-334 [Full text]  
• (2002). Celecoxib: Equally Efficacious, Less GI Toxic Than Other NSAIDs. Journal Watch Dermatology 2002: 9-9 [Full text]  
• (2002). Celecoxib: Equally Efficacious, Less GI Toxic Than Other NSAIDs. JWatch General 2002: 3-3 [Full text]  
• Jones, R. (2002). Efficacy and safety of COX 2 inhibitors. BMJ 325: 607-608 [Full text]  

Rapid Responses:

Read all Rapid Responses

misleading ?

Alessandro Calderan
bmj.com, 23 Sep 2002 [Full text]

Missing the point?

Jeremy J Black
bmj.com, 24 Sep 2002 [Full text]

New Cox 2 data

David J Walker
bmj.com, 26 Sep 2002 [Full text]

"Bad planning?"

Ebbe Englev
bmj.com, 30 Sep 2002 [Full text]

Celecoxib safer? Still not proven!

Arnold G Zermansky
bmj.com, 4 Oct 2002 [Full text]

On presentation and analysis

Michael L. Jenkinson
bmj.com, 7 Oct 2002 [Full text]

Assessing the risk of GI complications with NSAIDs is still problematic

Neal Maskrey, et al.
bmj.com, 9 Oct 2002 [Full text]

Review is more favorable than data

Christoph Pechlaner
bmj.com, 13 Oct 2002 [Full text]

Re: On presentation and analysis

Jonathan J Deeks, et al.
bmj.com, 15 Oct 2002 [Full text]

Celebrex’s relative GI safety is overstated?

Scott Metcalfe, et al.
bmj.com, 16 Oct 2002 [Full text]

A Missed Opportunity

James M Wright
bmj.com, 22 Oct 2002 [Full text]

Problems compromising the review's validity

Peter Jüni, et al.
bmj.com, 29 Oct 2002 [Full text]

On presentation and analysis

Michael L Jenkinson, et al.
bmj.com, 30 Oct 2002 [Full text]

Absence of evidence versus evidence of absence

Peter Jüni, et al.
bmj.com, 31 Oct 2002 [Full text]

Accolade

Robert I. Rudolph, M.D., FACP
bmj.com, 1 Nov 2002 [Full text]

Coxibs gastrointestinal safety: worth spending time on 3 months data?

Giulio Formoso, et al.
bmj.com, 9 Nov 2002 [Full text]

Study reports: clarification, correction and additional sources

Jonathan J Deeks
bmj.com, 13 Nov 2002 [Full text]

On eradicating publication bias, and the realities of independent reviews

Jonathan J Deeks
bmj.com, 15 Nov 2002 [Full text]

Re: On presentation and analysis

Michael L Jenkinson
bmj.com, 18 Dec 2002 [Full text]